Positron emission tomography for urological tumours

BJU International

Volumn 92, Issue 2, 2003, Pages 159-164

  Hain, S F ^a,b   Maisey, M N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ANDROGEN; CHOLINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER 1; HORMONE; METHIONINE; TRACER; TUMOR MARKER;

BLADDER CANCER; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CHOLINE UPTAKE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG EXCRETION; FIBROSIS; GLYCOLYSIS; HUMAN; IMAGE QUALITY; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; KIDNEY CYST; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; NON SEMINOMATOUS GERMINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; OSTEOSCLEROSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN PHOSPHORYLATION; REVIEW; SOFT TISSUE DISEASE; TESTIS CANCER; TREATMENT OUTCOME; TUMOR VOLUME; URINARY TRACT CANCER;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; URINARY BLADDER NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 0037825927     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04284.x     Document Type: Review

References (43)

1. Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorocic Surg 1999; 67: 790-7
2. Mikhaeel NG, Timothy AR, Hain S, O'Doherty MJ, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma. Leukaemia Lymphoma 2000; 39: 543-53
3. Hain SF, O'Doherty MJ, Timothy AR et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000; 83: 863-9
4. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18 fluorine-labelled deoxyglucose. J Urol 1996; 155: 994-8
5. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57: 108-11
6. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002; 86: 512-6
7. Oyama N, Akino H, Suzuki Y et al. The increased accumulation of [18F]Fluorodeoxyglucose in untreated prostate cancer. Jap J Clin Oncol 1999; 29: 623-9
8. Heicappell R, Muller-Mattheis V, Reinhardt M et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)]-2-deoxy-D-glucose. Eur Urol 1999; 36: 582-7
9. Sanz G, Rables JE, Gimenez M, Arcena J, Sanchez D, Rodriguez-Rubio F. Positron emission tomography with 18 fluorine-labelled deoxyglucose: utility in localized and advance prostate cancer. BJU Int 1999; 84: 1028-31
10. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer, initial findings of PET with 2-deoxy-[F-18] fluoro-D-glucose. Radiology 1996; 199: 751-6
11. Yeh SD, Imbriaco M, Larson SM et al. Detection of bony metastases of androgen-independent prostate cancer by FDG-PET. Nucl Med Biol 1996; 23: 693-7
12. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-9
13. Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18F FDG-PET for the assessment of residual masses on CT after treatment of lymphomas. Ann Oncol 2000; 11: S147-S150
14. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36: 31-5
15. Schelling M, Avril N, Nahrig J et al. Positron emission tomography using [(18)F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 1689-95
16. Oyama N, Akino H, Suzuki Y et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Comm 2001; 22: 963-9
17. Nunez R, Macapinlac HA, Yeung HW et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nuclear Med 2002; 43: 46-55
18. Kotzerke J, Prang J, Neumaier B et al. Experience with carbon-11 choline positron emission tomography in prostate cancer. EJNM 2000; 27: 1415-9
19. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using choline-11-choline. J Nucl Med 1998; 39: 990-5
20. DeGrado TR, Coleman RE, Wang S et al. Synthesis and evaluation of 18F-labelled choline as an oncological tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61: 110-7
21. Oyama N, Akino H, Kanamaru H et al. "C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43: 181-6
22. Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. Positron emission tomography in the diagnosis of renal cell carcinoma. Urologe 1996; 35: 146-50
23. Ramdave S, Thomas GW, Berlangiere SU et al. Clinical role of F-18 Fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166: 825-30
24. Miyakita H, Tokunaga M, Onda H et al. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002; 9: 15-8
25. Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischmann AJ, Lee MJ. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52: 510-5
26. Hain SF, Gleadle J, Maisey MN. FDG-PET in the differentiation of thrombus and tumour in renal cell carcinoma. Clin Nucl Med 1999; 24: 819-20
27. Safaei A, Figlin R, Hoh CK et al. The usefulness of F-18 deoxyglucose wholebody positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 2002; 57: 56-62
28. Seto E, Segall GM, Terris MK. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan. Urology 2000; 55: 286
29. Poggi MM, Patronas N, Buttman JA, Hewitt SM, Fuller B. Intramedullary spinal cord metastases from renal cell carcinoma: detection by positron emission tomography. Clin Nucl Med 2001; 26: 837-9
30. Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe 1999; 38: 46-50
31. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 Fluorodeoxyglucose positron emission tomography in patients with bladder cancer. EJNM 1997; 24: 615-20
32. Ahlstrom H, Malmstrom PU, Letocha H, Andersson J, Langstrom B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996; 37: 180-5
33. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography of residual radiological abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 1996; 14: 1637-41
34. Cremerius U, Effert PJ, Adam G et al. FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med 1998; 39: 815-22
35. Sugawara Y, Zasadny KR, Grossman HB et al. Germ cell tumour. differentiation of viable tumour, mature teratoma and necrotic tissue with FDG PET and kinetic modelling. Radiology 1999; 211: 249-56
36. De Santis M, Bokemeyer C, Becherer A et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19: 3740-4
37. Lodge MA, Lucas JD, Marsden PK et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26: 22-30
38. Bokmeyer C, Kollmannsberger C, Oechsle K et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F] FDG PET. Br J Cancer 2002; 86: 506-11
39. Hain SF, O'Doherty MJ, Timothy A et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000; 27: 590-4
40. Warde P, Jewett MA. Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 1998; 25: 425-33
41. Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumours. Urology 1994; 44: 548-52
42. Cremerius U, Wildberger JE, Borchers H et al. Does positron emission tomography using 18-Fluoro-2-deoxyglucose improve clinical staging of testicular cancer? results in 50 patients. Urology 1999; 54: 900-4
43. Albers P, Bender H, Yilmaz H et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumours. Urology 1999; 53: 808-11